IFP Advisors Inc Has $2.67 Million Stock Holdings in Bristol Myers Squibb Company $BMY

IFP Advisors Inc raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 57.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,476 shares of the biopharmaceutical company’s stock after acquiring an additional 18,060 shares during the period. IFP Advisors Inc’s holdings in Bristol Myers Squibb were worth $2,669,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth $32,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Bristol Myers Squibb during the 3rd quarter worth $35,000. Finally, Garner Asset Management Corp acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to roll out Claude Enterprise across its global operations, giving more than 30,000 employees access to AI tools aimed at speeding up drug discovery, development, manufacturing, and commercial work. Article: Bristol Myers Squibb Announces Strategic Agreement with Anthropic
• Positive Sentiment: The company said it will unveil new data at ASCO 2026, highlighting the strength of its oncology portfolio and next-generation pipeline, which could reinforce confidence in future cancer-drug growth. Article: Bristol Myers Squibb to Unveil New Data at ASCO 2026
• Neutral Sentiment: Market commentary continues to center on the balance between Bristol Myers Squibb’s pipeline potential and patent-expiration risks, keeping investor sentiment tied to upcoming data readouts and execution. Article: How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on BMY shares. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Morgan Stanley reissued an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. HSBC boosted their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald boosted their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $59.58 on Friday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The business has a 50-day simple moving average of $58.47 and a two-hundred day simple moving average of $55.83. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock has a market cap of $121.67 billion, a PE ratio of 16.74, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the firm earned $1.80 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.